Significant improvement in HbA1c in a morbidly obese type 2 diabetic patient after gastric bypass surgery despite relatively small weight loss

Diabetes Care ◽  
1999 ◽  
Vol 22 (4) ◽  
pp. 651-651 ◽  
Author(s):  
N. I. Khateeb ◽  
M. S. Roslin ◽  
D. Chin ◽  
N. Khan ◽  
H. Anhalt
2012 ◽  
Vol 26 (8) ◽  
pp. 2231-2239 ◽  
Author(s):  
Fabiola Romero ◽  
Joana Nicolau ◽  
Lílliam Flores ◽  
Roser Casamitjana ◽  
Ainitze Ibarzabal ◽  
...  

2012 ◽  
Vol 256 (6) ◽  
pp. 1023-1029 ◽  
Author(s):  
Amanda Jiménez ◽  
Roser Casamitjana ◽  
Lílliam Flores ◽  
Judith Viaplana ◽  
Ricard Corcelles ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
Mirella P. Hage ◽  
Bassem Safadi ◽  
Ibrahim Salti ◽  
Mona Nasrallah

Bariatric surgery is currently the most effective and durable therapy for obesity. Roux-en-Y gastric bypass surgery, the most commonly performed procedure worldwide, causes substantial weight loss and improvement in several comorbidities associated with obesity, especially type 2 diabetes. Several mechanisms are proposed to explain the improvement in glucose metabolism after RYGB surgery: the caloric restriction and weight loss per se, the improvement in insulin resistance and beta cell function, and finally the alterations in the various gastrointestinal hormones and adipokines that have been shown to play an important role in glucose homeostasis. However, the timing, exact changes of these hormones, and the relative importance of these changes in the metabolic improvement postbariatric surgery remain to be further clarified. This paper reviews the various changes post-RYGB in adipokines and gut peptides in subjects with T2D.


Author(s):  
Yeon Lee ◽  
Yoonseok Heo ◽  
Ji-Ho Choi ◽  
Sunghyouk Park ◽  
Kyoung Kim ◽  
...  

Irisin is a myokine with potential anti-obesity properties that has been suggested to increase energy expenditure in obese patients. However, there is limited clinical information on the biology of irisin in humans, especially in morbidly obese patients undergoing bariatric surgery. We aimed to assess the association of circulating irisin concentrations with weight loss in obese patients undergoing bariatric surgery. This was a pilot, single-centre, longitudinal observational study. We recruited 25 morbidly obese subjects who underwent Roux-en-Y gastric bypass surgery (RYGBP), and blood samples from 12 patients were taken to measure serum irisin concentrations before, and one and nine months after surgery. Their clinical characteristics were measured for one year. The preoperative serum irisin concentration (mean 1.01 ± 0.23 μg/mL, range 0.73–1.49) changed bidirectionally one month after RYGBP. The mean concentration at nine months was 1.11 ± 0.15 μg/mL (range 0.92–1.35). Eight patients had elevated irisin levels compared with their preoperative values, but four did not. Elevations of irisin levels nine months, but not one month, after surgery, were associated with lower preoperative levels (p = 0.016) and worse weight reduction rates (p = 0.006 for the percentage excess weight loss and p = 0.032 for changes in body mass index). The preoperative serum irisin concentrations were significantly correlated with the percentage of excess weight loss for one year (R2 = 0.612; p = 0.04) in our study. Our results suggest that preoperative circulating irisin concentrations may be at least in part associated with a weight loss effect of bariatric surgery in morbidly obese patients. Further large-scale clinical studies are needed to ratify these findings.


2008 ◽  
Vol 247 (2) ◽  
pp. 270-275 ◽  
Author(s):  
Rosa Morínigo ◽  
Josep Vidal ◽  
Antonio M. Lacy ◽  
Salvadora Delgado ◽  
Roser Casamitjana ◽  
...  

1986 ◽  
Vol 3 (3) ◽  
pp. 259-267 ◽  
Author(s):  
Mollie G. DeLozier ◽  
Richard G. Israel ◽  
Kevin F. O’Brien ◽  
Robert A. Shaw ◽  
Walter J. Pories

This investigation quantified body composition and aerobic capacity and examined the interrelationships of these measures in 20 morbidly obese females (M age = 34.6 yrs) prior to gastric bypass surgery. Fifteen subjects were hydrostatically weighed at residual lung volume in order to determine body composition. Eighteen subjects performed a maximal modified progressive treadmill test to determine aerobic capacity. Results indicated that the 15 subjects who were weighed hydrostatically were heavier (M wt = 132.34 kg) and fatter (M % fat = 53.18) than any previously described individuals. Relative weight, which is used as a criterion to determine surgery eligibility, was not significantly (p > .05) correlated to percent body fat. Mean aerobic capacity (V̇O2 = 14.99 ml • kg-1 mir-1) was comparable to Class III cardiac patients and was limited by the individuals’ extreme body weight. Since relative weight was shown to be an insensitive measure of obesity, it is recommended that percent fat be measured and used as a means to determine eligibility for gastric bypass surgery. Further study of these individuals is warranted in order to determine what effects large weight loss following surgery will have on parameters of body composition and aerobic capacity. Understanding how large weight loss affects these parameters will aid in designing effective postsurgical exercise rehabilitative programs for future patients.


2012 ◽  
Vol 22 (11) ◽  
pp. 1723-1729 ◽  
Author(s):  
Kathleen Yip ◽  
Leslie Heinberg ◽  
Victoria Giegerich ◽  
Philip R. Schauer ◽  
Sangeeta R. Kashyap

2006 ◽  
Vol 27 (2) ◽  
pp. 114-121 ◽  
Author(s):  
Jung-Jun Park ◽  
Jason R. Berggren ◽  
Matthew W. Hulver ◽  
Joseph A Houmard ◽  
Eric P. Hoffman

Obesity is associated with insulin resistance in skeletal muscle; accordingly, weight loss dramatically improves insulin action. We sought to identify molecular remodeling of muscle commensurate with weight loss that could explain improvements in insulin action. Muscle from morbidly obese women was studied before and after gastric bypass surgery. Gastric bypass surgery significantly reduced body mass by ∼45% and improved insulin action. We then assessed mRNA profiles using a stringent statistical analysis (statistical concordance with three probe set algorithms), with validation in a cross-sectional study of lean ( n = 8) vs. morbidly obese ( n = 8) muscle. Growth factor receptor-bound protein 14 (GRB14), glycerol-3-phosphate dehydrogenase 1 (GPD1), and growth differentiation factor 8 (GDF8; myostatin) significantly decreased ∼2.4-, 2.2-, and 2.4-fold, respectively, after weight loss (gastric bypass). Increased expression of these transcripts was associated with increased obesity in the cross-sectional group (lean vs. morbidly obese muscle). Each transcript was validated by real-time quantitative RT-PCR assays in both study groups. Using Ingenuity Pathway Analysis, we show that all three transcripts are involved in the same regulatory network including AKT1, IGF1, TNF, PPARG, and INS. These results suggest that GRB14, GPD1, and GDF8 are weight loss-responsive genes in skeletal muscle and that the observed transcriptional modulation of these would be expected to improve insulin signaling, decrease triglyceride synthesis, and increase muscle mass, respectively, with weight loss. Thus our data provide a possible regulatory pathway involved in the development of insulin resistance in the morbidly obese state, and improvement of insulin resistance with weight loss.


Sign in / Sign up

Export Citation Format

Share Document